OBJECTIVES: Recent literature suggests an increased risk of diabetes following smoking cessation. Our objective was to compare the risk of developing diabetes among obese smokers using bupropion versus varenicline as well as other predictors during the first 3 years post-cessation. METHODS: A population-based retrospective cohort study was conducted using the General Electric (GE) electronic medical record database (2006 -2011). The cohort consisted of obese adult smokers newly initiating use of a smoking cessation medication: bupropion versus varenicline without a diabetes diagnosis at baseline. The outcome variable was time to developing diabetes following first prescription with a 3-year follow up. Chi-square tests were conducted to assess the frequency distribution of sample characteristics and association with diabetes development. Univariate survival analyses using Kaplan-Meier survival curve were conducted and log-rank test was used to assess significance. Cox Proportional Hazard (PH) regression model was carried out after evaluating PH assumption by Schoenfeld residual test. Interaction terms were included in the PH regression model if assumption was violated. RESULTS: The sample comprised of 91,899 individuals. A total of 3,668 (crude diabetes incidence rate: 13.3 per 1,000 person-years) obese smokers developed diabetes in 3 years. Abstinence at 12 months did not meet the PH assumption and interaction was created for this variable in the final Cox model. There was no statistically significant difference in diabetes risk using bupropion versus varenicline (Hazard Ratio: 1.408 95% Confidence Interval: 0.963 -2.058). Non-primary care group (1.271 [1.069 -1.511]), male (1.174 [1.004 -1.373]), non-white (1.197 [1.015 -1.410]), age group (40 -64) (0.803 [0.656 -0.984]), abstinence at 12 months (0.758 [0.604 -0.952]), hypertension (1.239 [1.017 -1.509]),and lung cancer (2.023 [1.024 -3.999])
OBJECTIVES: Both biphasic human insulin 30 (BHI30) and biphasic insulin aspart (BIAsp30) serve an effective treatment option in patients with T2DM and their relative efficacy has been investigated in randomized clinical trials (RCTs). The aim of our analysis was to compare efficacy and safety of BIAsp30 with BHI30 on the basis of non-interventional trials. METHODS: Systematic search in PubMed, Medline and CENTRAL was carried out until November 2011. Non-interventional trials comparing either BIAsp30 with BHI30 in a parallel design or assessing a replacement therapy with one insulin preparation after suboptimal response to the other were included. RESULTS: Eight studies met the inclusion criteria; three compared directly BIAsp30 with BHI30, five assessed BIAsp30 after suboptimal treatment with BHI30. No studies evaluating BHI30 after BIAsp30 were identified. Meta-analysis of parallel studies demonstrated superiority of BIAsp30 over BHI30 with respect to the reduction of HbA1c (3 studies; WMD = -0.16% [-0.24; -0.08]) without increased risk of hypoglycemic episodes. Switching from BHI30 to BIAsp30 was associated with noticeable improvement in HbA1c level (3 studies; WMD = -1.69% [-1.94; -1.45]), fasting glucose (2 studies; -3.20 mmol/l [-3.75; -2.65]) and post-prandial glucose level (2 studies; WMD = -4.66 mmol/l [-4.74; -4.58] ). The largest study demonstrated that the use of BIAsp30 instead of BHI30 revealed statistically significant reduction in the incidence of both minor (MD = -5.7 episodes/patient/year; p<0.0001) and major hypoglycemic episodes (MD = -0.331; p<0.0001). BIAsp 30 was not associated with a weight gain either in parallel design nor in studies assessing sequential treatment. CONCLUSIONS: In this analysis, including real clinical practice studies BIAsp30 was more effective than BHI30 in the control of T2DM. Additionally, BIAsp30 was a good alternative for patients with failure or suboptimal response to previous insulin therapy with BHI30.
PDB10 SOCIAL NETWORKS BOOST DIABETES EDUCATION AND REDUCE HBA1C AND BLOOD SUGAR
Shaya FT 1 , Chirikov VV 1 , Howard D 1 , Foster C 1 , Snitker S 2 , Costas J 3 , Kucharski K 3 , Tangirala K 3 , Frimpter J 3 1 University of Maryland School of Pharmacy, Baltimore, MD, USA, 2 University of Maryland School of Medicine, Baltimore, MD, USA, 3 Sanofi US, Bridgewater, NJ, USA OBJECTIVES: The goal of the "Diabetes Peer to Peer (P2P ® ) Study" was to assess the effect of social networks for diabetes information sharing on the improvement of diabetes management in patients with type 2 diabetes in the Baltimore metropolitan area. METHODS: In this prospective cohort study enrolling patients with diabetes, those in the intervention group (P2P ® ) were asked to recruit peers, form small groups, and attend monthly diabetes education sessions, emphasizing peer-support. Patients in the control group were recruited individually to attend standard diabetes education sessions. The primary outcomes were changes in Hemoglobin A1C (HbA1c) and blood glucose. Secondary outcomes included clinical indicators (blood pressure, BMI), functional status, self-efficacy, perceived cohesion, social network connectedness, and diabetes knowledge. Socio-demographics, drug history, and comorbidities were also recorded. Multivariate regression models, finalized after a stepwise selection process, were built to assess mean absolute changes in HbA1c and blood glucose at the first follow-up, at three months. RESULTS: Of a total of 136 enrolled, the intervention patients (68) had more metformin use, higher BMI, lower social network scores, and lower diabetes knowledge at baseline. All other baseline characteristics were evenly distributed between arms. At follow-up, P2P ® patients had a larger reduction in HbA1c (-0.47 vs. -0.31%, P=0.17) and blood glucose (-9.1 vs. -2.4 mg/dL, P=0.05) than the controls. In multivariate adjusted models, P2P ® was associated with a statistically significantly larger mean reduction in HbA1c (-0.33%, P<0.01) and blood glucose (-8.6 mg/dL, P<0.01), than the control. Marital status, insulin use, high baseline Hba1c, and good physical functional status were associated with a significant drop in Hba1c and blood glucose. CONCLUSIONS: The social networks, as opposed to the individual approach to diabetes education, prove more effective at reducing patients' HbA1c and blood glucose at 3-months follow-up. ($20,371 vs. $21,210 [$15,847 vs. $15,883] ; P=0.548 [P=0.985]). CONCLUSIONS: This study suggests that initiating GLA in T2DM Medicaid patients was associated with better treatment persistence and adherence than DET. However, the findings are exploratory, limited by their retrospective nature and the lack of key clinical data such as A1C.
PDB11 COMPARATIVE STUDY OF INITIATION OF BASAL ANALOG INSULIN AND ASSOCIATED OUTCOMES AMONG MEDICAID PATIENTS WITH TYPE-2 DIABETES MELLITUS

PDB13 A COHORT ASSESSMENT OF CHILDREN BORN SMALL FOR GESTATIONAL AGE OR WITH INTRAUTERINE GROWTH RETARDATION TREATED WITH GROWTH HORMONE IN COLOMBIA
Ortiz Picon T 1 , Duran P 2 , Jaimes GC 3 , Mejia Zapata LM 4 , Manrique LA 5 , Suarez MB 6 , Gutierrez-Ardila MV 7 1 Hospital Militar Bogota, Colombia, 2 Fundacion Cardio Infantil, Bogota, Cundinamarca, Colombia, 3 Hospital Militar Central, Bogota, Cundinamarca, Colombia, Cali, Colombia, 5 Centro Médico Farallones, Cali, Valle, Colombia, 6 Hospital Naval -Cirujanos y Pediatras Asociados, Barranquilla, Colombia, 7 Pfizer S.A.S., Bogota, Colombia OBJECTIVES: To compare the outcomes of a cohort of children born small for gestational age and/or with intrauterine growth retardation (SGA/IUGR) treated with growth hormone (GH) in Colombia with a global cohort from KIGS (Pfizer International Growth Database) population of the same characteristics (Ranke et al, 2010), over 1 and 2 years. METHODS: Two Colombian children cohorts, diagnosed with SGA/IUGR and treated with GH, included in KIGS, were assessed: cohort 1 (n=39) with 1-year follow-up and cohort 2 (n=16) with 2-year follow-up. The cohort characteristics (clinical outcomes in Standard Deviation Score (SDS) for height, weight, body mass index, and growth rate [cm/year]) were described at the time of initiation of therapy and at 1 and 2 years follow-up, and were compared with children from the global cohort. RESULTS: Cohort 1 began treatment at 6.63 years (average) with a height of -3.20 SDS and weight of -2.42 SDS, growth rate reported after one year of treatment was 0.22cm lower than the global cohort (8.18 vs 8.4 cm/yr respectively); Cohort 2 with, began treatment at 5.28 years (average) with a height of -3.83 SDS and a weight of -3.73 SDS; reported growth rate was 0.27 cm lower than the global cohort in the 1-year follow-up and 0.63 cm over the 2-year follow-up (8.23 vs. 8.5 and 7.63 vs. 7.00 cm/year respectively). Regarding the height difference (SDS), cohort 1 was 0.12 SDS lower than the global cohort (0.58 vs. 0.7) and cohort 2 was 0.2 SDS lower than the first year of follow-up and 0.05 SDS higher than the 2 year follow-up (0.5 vs. 0.7 and 0.45 vs. 0.4, respectively). CONCLUSIONS: This analysis demonstrates that GH administration has a positive effect on height in children diagnosed SGA/IUGR in Colombia; they respond to therapy similarly to a globally treated cohort.
